Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy. Issue 3 (12th February 2021)

• Record Type: Journal Article
• Authors: Hu, Zhongbo; VanHeyst, Kristen A.; Dalal, Jignesh; Hackney, Lisa
• Is Part Of: Clinical case reports. Volume 9:Issue 3(2021)
• Page Start: 1118
• Page End: 1122
• Publication Date: 2021-02-12
• Subjects: ALL R3 -- Down syndrome -- Relapsed acute lymphoblastic leukemia -- remission; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.3678
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: DS‐ALL has a higher rate of relapse and treatment‐related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis. Transient long‐term remission after ALL relapse due to partial chemotherapy combined severe infection is rare. Abstract : DS‐ALL has a higher rate of relapse and treatment‐related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis. Transient long‐term remission after ALL relapse due to partial chemotherapy combined severe infection is rare.